Published in
BioMed Central, Trials, 1(17), 2016
DOI: 10.1186/s13063-016-1195-6
Links
- ORCID
- BioMed Central
- [eprints.whiterose.ac.uk] | PDF
- [europepmc.org] | PDF
- [www.ncbi.nlm.nih.gov] | PDF
Tools
Erratum to: ‘Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial
Journal article published in 2016 by
Denise A. Yardley,
Adam Brufsky,
Robert E. Coleman,
Pierfranco F. Conte 
,
Javier Cortes,
Stefan Glück,
Jean-Mark A. Nabholtz,
Joyce O’Shaughnessy,
Robert M. Beck,
Amy Ko,
Markus F. Renschler,
Debora Barton,
Nadia Harbeck
,
Javier Cortes,
Stefan Glück,
Jean-Mark A. Nabholtz,
Joyce O’Shaughnessy,
Robert M. Beck,
Amy Ko,
Markus F. Renschler,
Debora Barton,
Nadia Harbeck
This paper is made freely available by the publisher.
Full text: Download
Data provided by 